Do KA - Search Results

1

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.

Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Kanagal-Shamanna R, et al. Among authors: do ka. Blood Cancer J. 2021 Mar 6;11(3):52. doi: 10.1038/s41408-021-00446-y. Blood Cancer J. 2021. PMID: 33677472 Free PMC article. No abstract available.

2

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. Ibrahim S, et al. Among authors: do ka. Blood. 2001 Jul 1;98(1):181-6. doi: 10.1182/blood.v98.1.181. Blood. 2001. PMID: 11418478 Free article.

3

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Manshouri T, et al. Among authors: do ka. Blood. 2003 Apr 1;101(7):2507-13. doi: 10.1182/blood-2002-06-1639. Epub 2002 Nov 21. Blood. 2003. PMID: 12446458 Free article.

4

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Kantarjian HM, Armitage JO, Albitar M. Giles FJ, et al. Among authors: do ka. Leuk Res. 2004 Jun;28(6):595-604. doi: 10.1016/j.leukres.2003.11.002. Leuk Res. 2004. PMID: 15120936

5

Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.

Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Albitar M, et al. Among authors: do ka. Cancer. 2004 Sep 1;101(5):999-1008. doi: 10.1002/cncr.20477. Cancer. 2004. PMID: 15329909 Free article.

6

Combined laser capture microdissection and serial analysis of gene expression from human tissue samples.

Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Cho-Vega JH, et al. Among authors: do ka. Mod Pathol. 2005 Apr;18(4):577-84. doi: 10.1038/modpathol.3800327. Mod Pathol. 2005. PMID: 15529182 Free article.

7

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Wierda W, et al. Among authors: do ka. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767647

8

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.

Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Faderl S, et al. Among authors: do ka. Blood. 2005 Dec 15;106(13):4303-7. doi: 10.1182/blood-2005-03-1010. Epub 2005 Aug 25. Blood. 2005. PMID: 16123221 Free article.

9

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.

Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. Wierda W, et al. Among authors: do ka. Cancer. 2006 Jan 15;106(2):337-45. doi: 10.1002/cncr.21554. Cancer. 2006. PMID: 16353201 Free article.

10

Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.

Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Tsimberidou AM, et al. Among authors: do ka. Cancer. 2006 Jul 1;107(1):125-35. doi: 10.1002/cncr.21931. Cancer. 2006. PMID: 16700034 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page